DRAP Issues Urgent Alert on Unsafe Syringes in Pakistan
Unsafe Syringes Recalled After DRAP Alert
The Drug Regulatory Authority of Pakistan (DRAP) has declared multiple batches of auto‑disable syringes unsafe, issuing a formal medical product alert. Testing by the Central Drugs Laboratory in Karachi revealed that several 3ml and 5ml syringes failed to meet required safety standards.
Faulty Syringe Batches Identified
The substandard syringes were traced to both international and local manufacturers, including:
- Jiangxi Fenglin Medical Appliances (China) – 3cc syringes
- Medila Elwakia International Company (Egypt) – 5ml syringes
- Shandong Care Medical (China) – 3ml syringes
- Additional suppliers from Punjab and Khyber Pakhtunkhwa also flagged for producing faulty syringes.
Public Health Risks
DRAP warned that the defective syringes could be reused due to faults in the auto‑disable mechanism, creating a dangerous risk of transmitting life‑threatening infections such as hepatitis and HIV.
Regulatory Action
- Immediate ban on the sale and use of the affected batches.
- Recall orders issued to manufacturers, importers, and distributors.
- Provincial health authorities instructed to remove unsafe syringes from the market.
Why This Matters
Unsafe syringes undermine Pakistan’s healthcare system by exposing patients to preventable infections. The DRAP alert emphasizes the importance of strict quality control and regulatory oversight in medical supplies.
Final Takeaway
The DRAP’s swift action highlights the urgent need for vigilance in healthcare safety. Patients, hospitals, and pharmacies must ensure that only certified, compliant syringes are used to protect against infection risks. This recall serves as a reminder that medical product safety is non‑negotiable in safeguarding public health.